ZURA
NASDAQ · Biotechnology
Zura Bio Ltd
$1.43
+0.03 (+1.78%)
Open$1.41
Previous Close$1.41
Day High$1.58
Day Low$1.35
52W High$7.44
52W Low$3.25
Volume—
Avg Volume3.73M
Market Cap440.73M
P/E Ratio—
EPS$-0.79
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,516.8% upside
Current
$1.43
$1.43
Target
$23.12
$23.12
$15.51
$23.12 avg
$31.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 178.15M | 170.40M | 174.38M |
| Net Income | 4.79M | 4.86M | 5.73M |
| Profit Margin | 2.7% | 2.9% | 3.3% |
| EBITDA | 8.96M | 8.92M | 9.38M |
| Free Cash Flow | 5.34M | 5.40M | 5.82M |
| Rev Growth | +24.5% | +6.4% | +20.2% |
| Debt/Equity | 0.26 | 0.34 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |